UK govt backs ventilator makers against potential IP complaints
16-04-2020
Canada authorises compulsory licences for COVID-19 shortfalls
27-03-2020
21-04-2020
Scotyard / Shutterstock.com
New legislation has been enacted to help in the efforts to deal with the COVID-19 outbreak, as Daphne Lainson and Nancy Pei of Smart & Biggar report.
On March 25, 2020, the government of Canada acted swiftly to enact legislation in response to COVID-19. The legislation, which was introduced into Parliament just the day before, brought sweeping changes to various aspects of Canadian law, including expanding the compulsory licensing framework in the Patent Act.
The Canadian Patent Act has permitted the grant of compulsory licences in four broad circumstances: (i) for a pharmaceutical patent, on application and payment of a nominal royalty (repealed in 1993); (ii) where there has been abuse of patent rights; (iii) for use by the government; and (iv) use for export of pharmaceutical products for humanitarian reasons.
The COVID-19 Emergency Response Act grants the Commissioner of Patents the power to authorise use of a patented invention to the extent necessary to respond to a public health emergency. This form of compulsory licensing builds on the existing framework that has allowed government use of a patented invention.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
compulsory licensing, Canada, Smart & Biggar, NAFTA, COVID-19, coronavirus